Nutritional status, body surface, and low lean body mass/body mass index are related to dose reduction and severe gastrointestinal toxicity induced by afatinib in patients with non-small cell lung cancer

Oncologist

Volumn 20, Issue 8, 2015, Pages 967-974

  Arrieta, Oscar ^a   de la Torre Vallejo, Martha ^a   López Maćias, Diego ^a   Orta, David ^a   Turcott, Jenny ^a   Macedo Pérez, Eleazar Omar ^a   Sánchez Lara, Karla ^a   Ramírez Tirado, Laura Alejandra ^a   Baracos, Vickie E ^b  

^a INSTITUTO NACIONAL DE CANCEROLOGÍA   (Mexico)

^b UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Afatinib; Gastrointestinal toxicity; Malnourishment; Non small cell lung cancer; Nutritional status; Phase II trial

Indexed keywords

AFATINIB; QUINAZOLINE DERIVATIVE;

ADULT; ARTICLE; BODY MASS; BODY SURFACE; COMPUTER ASSISTED TOMOGRAPHY; CONSTIPATION; DIARRHEA; DRUG DOSE REDUCTION; DYSGEUSIA; DYSPHAGIA; FEMALE; FOLLOW UP; GASTROINTESTINAL TOXICITY; HUMAN; LEAN BODY WEIGHT; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MUCOSA INFLAMMATION; NAUSEA AND VOMITING; NON SMALL CELL LUNG CANCER; NUTRITIONAL STATUS; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; XEROSTOMIA; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIAL; GASTROINTESTINAL DISEASES; LUNG NEOPLASMS;

BODY MASS INDEX; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; GASTROINTESTINAL DISEASES; HUMANS; LUNG NEOPLASMS; MALE; NUTRITIONAL STATUS; QUINAZOLINES;

EID: 84940022374     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2015-0058     Document Type: Article

References (28)

1. Siegel R, Ma J, Zou Z et al. Cancer statistics, 2014. CA Cancer J Clin 2014;64:9-29.
2. Ferlay J, Shin HR, Bray F et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010;127:2893-2917.
3. Arrieta O, Guzman-de Alba E, Alba-Lopez LF et al. National consensus of diagnosis and treatment of non-small cell lung cancer [in Spanish]. Rev Invest Clin 2013;65(suppl 1):S5-S84.
4. Arrieta O, Nunez-Valencia C, Reynoso-Erazo L et al. Health-related quality of life in patients with lung cancer: Validation of the Mexican-Spanish version and association with prognosis of the EORTC QLQ-LC13 questionnaire. Lung Cancer 2012;77: 205-211.
5. Schiller JH, Harrington D, Belani CP et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002;346:92-98.
6. Dziadziuszko R, Jassem J. Epidermal growth factor receptor (EGFR) inhibitors and derived treatments. Ann Oncol 2012;23(suppl 10):1193-1196.
7. Yu HA, Arcila ME, Rekhtman N et al. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR mutant lung cancers. Clin Cancer Res 2013;19: 2240-2247.
8. Miller VA, Hirsh V, Cadranel J et al. Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): A phase 2b/3 randomised trial. Lancet Oncol 2012;13: 528-538.
9. Wu YL, Zhou C, Hu CP et al. Afatinib versus cisplatin plusgemcitabineforfirst-linetreatmentof Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): An open-label, randomised phase 3 trial. Lancet Oncol 2014;15:213-222.
10. Sequist LV, Yang JC, Yamamoto N et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol 2013;31: 3327-3334.
11. Yang JC, Hirsh V, Schuler M et al. Symptom control and quality of life in LUX-Lung 3: A phase III study of afatinib or cisplatin/pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutations. J Clin Oncol 2013;31: 3342-3350.
12. Sanchez-Lara K, Turcott JG, Juarez-Hernandez E et al. Effects of an oral nutritional supplement containing eicosapentaenoic acid on nutritional and clinical outcomes in patients with advanced non-small cell lung cancer: Randomised trial. Clin Nutr 2014;33:1017-1023.
13. Sanchez-Lara K, Turcott JG, Juarez E et al. Association of nutrition parameters including bio-electrical impedance and systemic inflammatory response with quality of life and prognosis in patients with advanced non-small-cell lung cancer: A prospective study. Nutr Cancer 2012;64: 526-534.
14. Prado CM, Lieffers JR, McCargar LJ et al. Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: A population-based study. Lancet Oncol 2008;9: 629-635.
15. Arrieta O, Michel Ortega RM, Villanueva-Rodriguez G et al. Association of nutritional status and serum albumin levels with development of toxicity in patients with advanced non-small cell lung cancer treated with paclitaxel-cisplatin chemotherapy: A prospective study. BMC Cancer 2010;10:50.
16. Cruz-Jentoft AJ, Baeyens JP, Bauer JM et al. Sarcopenia: European consensus on definition and diagnosis: Report of the European Working Group on sarcopenia in older people. Age Ageing 2010;39: 412-423.
17. Fearon K, Strasser F, Anker SD et al. Definition and classification of cancer cachexia: An international consensus. Lancet Oncol 2011;12: 489-495.
18. Antoun S, Baracos VE, Birdsell L et al. Low body mass index and sarcopenia associated with dose-limiting toxicity of sorafenib in patients withrenalcellcarcinoma. AnnOncol2010;21: 1594-1598.
19. Mourtzakis M, Prado CM, Lieffers JR et al. A practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine care. Appl Physiol Nutr Metab 2008;33:997-1006.
20. Shen W, Punyanitya M, Wang Z et al. Total body skeletal muscle and adipose tissue volumes: Estimation from a single abdominal cross-sectional image. J Appl Physiol (1985) 2004;97: 2333-2338.
21. Luo J, Chen YJ, Narsavage GL et al. Predictors of survival in patients with non-small cell lung cancer. Oncol Nurs Forum 2012;39:609-616.
22. Yang JC, Shih JY, Su WC et al. Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): A phase 2 trial. Lancet Oncol 2012;13:539-548.
23. Prado CM, Baracos VE, McCargar LJ et al. Sarcopenia as a determinant of chemotherapy toxicityandtimetotumorprogressioninmeta-static breast cancer patients receiving capecita-bine treatment. Clin Cancer Res 2009;15: 2920-2926.
24. Massicotte MH, Borget I, Broutin S et al. Body composition variation and impact of low skeletal muscle mass in patients with advanced medullary thyroid carcinoma treated with vandetanib: Results from a placebo-controlled study. J Clin Endocrinol Metab 2013;98:2401-2408.
25. Mir O, Coriat R, Blanchet B et al. Sarcopenia predicts early dose-limiting toxicities and pharmacokinetics of sorafenib in patients with hepatocellular carcinoma. PLoS One 2012;7: e37563.
26. Huillard O, Mir O, Peyromaure M et al. Sarcopenia and body mass index predict sunitinib-induced early dose-limiting toxicities in renal cancer patients. Br J Cancer 2013;108:1034-1041.
27. Tan BH, Birdsell LA, Martin Let al. Sarcopenia in an overweight or obese patient is an adverse prognostic factor in pancreatic cancer. Clin Cancer Res 2009;15:6973-6979.
28. Sabel MS, Lee J, Cai S et al. Sarcopenia as a prognostic factor among patients with stage III melanoma. Ann Surg Oncol 2011;18:3579-3585.